The level of BALF TIMP-2 was significant higher among patients with lung cancer than patients with benign diseases (4.0 ± 0.4 ng/ml versus 2.8 ± 0.3 ng/ml, P = 0.0371; Figure 2A). Here, TIMP2 is linked to lung carcinoma.